Breaking Finance News

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) target price raised to $26.00, reported today by HC Wainwright

Yesterday Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) traded 2.43% higher at $18.50. The company’s 50-day moving average is $16.95 and its 200-day moving average is $14.81. The last stock close price is up 27.98% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 762,836 shares of the stock were exchanged, down from an average trading volume of 869,592

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) had its target price raised to $26.00 by HC Wainwright in a report released Friday October 07, 2016. The new target price indicates a possible upside of 0.41% based on the company's last stock close price.

Previously on 10/5/2016, Zacks Investment Research reported about Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) raised the target price from $0.00 to $20.00. At the time, this indicated a possible upside of 0.12%.

See Chart Below

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)

Lexicon Pharmaceuticals, Inc. has a 52 week low of $7.65 and a 52 week high of $19.62 The company’s market cap is currently $0.

General Information About Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)

Lexicon Pharmaceuticals, Inc. (Lexicon) is a biopharmaceutical company. The Company focuses on the development of treatments for human disease. The Company is engaged in the development of two drug candidates: telotristat etiprate (LX1032) and sotagliflozin (LX4211). The Company's telotristat etiprate, is an orally delivered small molecule drug candidate, as a treatment for carcinoid syndrome. LX1032 inhibits tryptophan hydroxylase (TPH), which is an orally-delivered small molecule compound that the Company is developing for the treatment of carcinoid syndrome. Sotagliflozin, or LX4211, which is an orally-delivered small molecule compound that the Company is developing for the treatment of type 1 and type 2 diabetes mellitus. LX2761 is an orally-delivered small molecule compound for the treatment of diabetes. LX9211 is an orally-delivered small molecule compound for the treatment of neuropathic pain. The Company's other programs include LX1033, LX2931 and LX7101.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *